Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Enikő Kakucs"'
Autor:
Erzsébet Lázár, Judit-Beáta Köpeczi, Enikő Kakucs, István Benedek, Szende Jakab, Annamária Pakucs, Cezara Tudor
Publikováno v:
Journal of Interdisciplinary Medicine, Vol 2, Iss 1, Pp 41-44 (2017)
This study presents a new method of combined growth factor mobilization with increased dose (15 μg/kg) of filgrastim and standard mono dose of plerixafor in subjects with multiple myeloma, Hodgkin or non-Hodgkin lymphoma. Efficient mobilization is a
Publikováno v:
Journal of Interdisciplinary Medicine, Vol 1, Iss 3, Pp 293-296 (2016)
We present the method of immunomagnetic stem cell separation with the ISOLEX 300i device (Isolex® 300i Magnetic Cell Selection System, Nextell Therapeutics Inc. Irvine California 21618 USA) and the results obtained using this method in patients admi
Autor:
Cezara-Iuliana Tudor, Erzsébet Lázár, Marius-Vasile Găzdac, Annamária Pakucs, Eszter Mild, Judit-Beáta Köpeczi, Enikő Kakucs, István Benedek
Publikováno v:
Journal of Interdisciplinary Medicine, Vol 2, Iss s4, Pp 45-47 (2017)
Stem cells are undifferentiated cells that can divide and become differentiated. Hematopoietic stem cells cannot transform into new stem cells such as cardiomyocytes or new heart valves, but they act through paracrine effects, by secreting cytokines
Autor:
Marius Găzdac, Cezara Tudor, Enikő Kakucs, Judit-Beáta Köpeczi, Eszter Mild, Erzsébet Lázár, István Benedek, Annamária Pakucs
Publikováno v:
Journal of Interdisciplinary Medicine, Vol 2, Iss s4, Pp 39-41 (2017)
Background: High-dose chemotherapy and autologous stem cell transplantation have become a standard curative treatment in various hematologic malignancies. Many factors can affect the success of mobilization and hematopoietic stem cell harvesting. Aim
Autor:
Annamária Pakucs, Erzsébet Lázár, Judit Beáta Köpeczi, Enikő Kakucs, István Benedek, Marius Găzdac, Eszter Mild, Cezara Tudor
Publikováno v:
Journal of Interdisciplinary Medicine, Vol 2, Iss s4, Pp 36-38 (2017)
Introduction: Autologous hematopoietic stem cell transplantation (ASCT) represents a standard therapy in the management of hematologic malignancies such as malignant lymphomas and has used for approximately three decades. The aim of this study was to
Autor:
Enikő, Kakucs1, I., Benedek2, Erzsébet, Benedek1, Judit Beáta, Köpeczi1, Aliz, Tunyogi1, Monica, Istrati1
Publikováno v:
Acta Medica Marisiensis. Aug2011, Vol. 57 Issue 4, p306-309. 4p. 3 Charts.
Autor:
Erzsébet Benedek, Zsuzsa Pap, Aliz-Beáta Tunyogi, Enikő Kakucs, Judit Beáta Köpeczi, I Benedek, Monica Istrati
Publikováno v:
Acta Medica Marisiensis, Vol 59, Iss 2, Pp 71-74 (2013)
Introduction: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder; the molecular hallmark of the disease is the BCR-ABL gene rearrangement, which usually occurs as the result of a reciprocal translocation between chromosomes 9 and
Autor:
I Benedek, Monica Istrati, Enikő Kakucs, Judit Beáta Köpeczi, Aranka Kurtus, Aliz Beáta Tunyogi, Erzsébet Benedek
Publikováno v:
Acta Medica Marisiensis, Vol 59, Iss 2, Pp 111-114 (2013)
Introduction: Plasmacytoid dendritic cell leukemia is a rare subtype of acute leukemia, which has recently been established as a distinct pathologic entity that typically follows a highly aggressive clinical course in adults. The aim of this report i
Autor:
I Benedek, Monica Istrati, Aliz-Beáta Tunyogi, Judith Beáta Köpeczi, Erzsébet Benedek, Aranka Kurtus, Enikő Kakucs
Publikováno v:
Acta Medica Marisiensis, Vol 59, Iss 3, Pp 169-171 (2013)
Introduction: Anemia is a common complication of malignant lymphomas, which could be a direct consequence of the disease or secondary to the myelosupressive chemotherapy. The aim of this study was to assess the effect of erythropoietin to treat anemi
Autor:
Judit Beáta Köpeczi, Erzsébet Benedek, I Benedek, Aliz Beáta Tunyogi, Enikő Kakucs, Monica Istrati
Publikováno v:
Acta Medica Marisiensis, Vol 59, Iss 2, Pp 91-93 (2013)
Introduction: Autologous haemopoietic stem cell transplantation (SCT) is an important treatment modality for patients with acute myeloid leukemia with low and intermediate risk disease. It has served advantages over allogenic transplantation, because